NCT07642856 Individualized Neuro-Modulation Paired With Cerebellar Therapy
| NCT ID | NCT07642856 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. |
| Condition | Cerebellar Ataxia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-30 |
| Primary Completion | 2032-07-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-06-30 with a primary completion date of 2032-07-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this project is to evaluate feasibility and preliminary efficacy of pairing personalized transcranial direct current stimulation (tDCS) with individualized rehabilitation therapy in people with cerebellar damage.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years * Males and Females * Disorders that predominantly affect the cerebellum: damage from stroke, tumor or degeneration (genetic or non-genetic causes, congenital hypoplasia). Exclusion Criteria: * Diagnoses or impairments that interfere with task execution or data interpretation. * Heart pacemaker or other MRI-incompatible implanted metal device * Metallic foreign body in their eye or head * Experience with severe claustrophobia * Experience discomfort from the MRI scan, such as excessive heating of tattoos * Seizures or history of seizure disorder * Alcohol or substance use disorder (self-report) * Diagnosed history of severe psychiatric disorder such as depression, schizophrenia (self-report) * Metallic foreign body in their eye or head (except the mouth e.g. dental fillings) * Specific medications: tricyclic anti-depressants or neuroleptic medication * Any medical condition (including orthopedic, pain, cardiopulmonary or other) that limits safe participation in exercise training
Contact & Investigator
Amy J Bastian, PhD, PT
PRINCIPAL INVESTIGATOR
Motion Analysis Lab in the Kennedy Krieger Institute
Frequently Asked Questions
Who can join the NCT07642856 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cerebellar Ataxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07642856 currently recruiting?
Yes, NCT07642856 is actively recruiting participants. Contact the research team at eversley@kennedykrieger.org for enrollment information.
Where is the NCT07642856 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT07642856 clinical trial?
NCT07642856 is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.. The principal investigator is Amy J Bastian, PhD, PT at Motion Analysis Lab in the Kennedy Krieger Institute. The trial plans to enroll 30 participants.